अमूर्त
Hypoxanthine of Ischemic Brain Edema Modified by Glibenclamide
Sun JingThe development of malignant brain edema is a leading cause of early clinical deterioration and death after ischemic stroke. Lesional swelling exacerbates tissue injury and portends poor long-term functional outcome after stroke. Malignant brain edema [1], the rapid clinical decline in the first 24–72 h after stroke due to mass-occupying tissue swelling, is a highly morbid sequela of large hemispheric stroke. Limited therapies exist for the treatment of brain edema.
अस्वीकृति: इस सारांश का अनुवाद कृत्रिम बुद्धिमत्ता उपकरणों का उपयोग करके किया गया है और इसे अभी तक समीक्षा या सत्यापित नहीं किया गया है।